Given the involvement of CFAP418 in BBS pathogenesis (9, 12, 13), we performed semiquantitative immunoblot analysis for BBS2, BBS4, and ARL13B, for which commercial antibodies are available. This evidence concerns the gene BBS4 and Bardet-Biedl syndrome.